Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BeOne Medicines
Merck Sharp & Dohme LLC
Nurix Therapeutics, Inc.
AbbVie
Rigshospitalet, Denmark
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
University of Chicago
Gilead Sciences
National Institutes of Health Clinical Center (CC)
University of Washington
Mayo Clinic
BeOne Medicines
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Mayo Clinic
Fundación Española de Hematología y Hemoterapía
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
Newave Pharmaceutical Inc
Schrödinger, Inc.
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
City of Hope Medical Center
BeOne Medicines
iOMEDICO AG
Eli Lilly and Company
AbbVie
Fondazione Italiana Linfomi - ETS
BeOne Medicines
BeOne Medicines
Acerta Pharma BV
Carna Biosciences, Inc.
University of Ulm
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University Hospital, Lille
University of Ulm
Acerta Pharma BV
Massachusetts General Hospital
French Innovative Leukemia Organisation
Massachusetts General Hospital
BeOne Medicines
Seoul National University Hospital
Fondazione Italiana Linfomi - ETS